

## Neoadjuvant Treatment

GUIDELINE	DOCUMENT	ORGANISATION/ COUNTRY	YEAR PUBLISHED
Neoadjuvant therapy	<a href="#">Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)</a>	National Institute for Health and Care Excellence (NICE), UK	2016

Comments:

This guidance re-emphasises the importance of discussing all ER-ve and HER2+ve breast cancer patients in the pre-operative MDT.

GUIDELINE	DOCUMENT	ORGANISATION/ COUNTRY	YEAR PUBLISHED
Neoadjuvant therapy	<a href="#">NACT Guideline</a>	Association of Breast Pathology, ABS, British Society of Breast Radiology & UK Breast Cancer Group, UK	2023

Comments:

Together with the UK Breast Cancer Group, the Association of Breast Pathology and the British Society of Breast Radiology, the ABS have produced a guidance document for Neoadjuvant Chemotherapy (NAC). It is designed to be a pragmatic document to help Breast Multidisciplinary Teams identify those patients who will benefit from NAC and those that will not. It also provides useful information about the delivery of NAC as well as guidance to help make decisions about surgery and radiotherapy after NAC. The format is concise and easy to read..

<b>Date</b>	January 2023
<b>Version</b>	2

The guideline title in the document column includes a hyperlink to the relevant guideline. Please view the document on the ABS website to follow these links.